Skip to main content
OpenTrials
Completed

NCT Number: NCT00320619

Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery

Individuals who undergo spine surgery often have a significant loss of blood and may require multiple blood transfusions. Research has shown that epsilon-aminocaproic acid (EACA) may reduce the amount of blood lost during surgery, which would decrease the number of blood transfusions required. This study will evaluate the safety and effectiveness of EACA at reducing blood loss and the need for blood transfusions in individuals undergoing spine surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

About this study

Spine surgery is often required to correct a number of diseases, including spondylosis, pseudoarthrosis, scoliosis, or other spinal deformities. Spine surgery is often associated with significant blood loss and individuals may require multiple blood transfusions during and following surgery. Blood transfusions are expensive and carry an increased risk of health complications, including fever, allergic reactions, or infections. Preliminary research has shown that EACA may be beneficial for individuals undergoing spine surgery. In addition, EACA appears to be safer and less expensive than other medications typically used to treat serious bleeding. The purpose of this study is to evaluate the safety and effectiveness of EACA at reducing the number of blood transfusions required during and following spine surgery in adults.

This study will enroll individuals who are undergoing spine surgery at Johns Hopkins Hospital. Prior to surgery, participants' demographic data and medical history will be collected. Participants will then be randomly assigned to receive either EACA or placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU). While in the hospital, participants will have blood drawn frequently for laboratory testing. They will receive blood transfusions as needed and will be closely monitored for blood loss and any medical, surgical, or transfusion complications. Outcome measurements related to the amount of transfused blood required and postoperative complications will be collected on the 8th day following surgery. Study participation will end on the day of hospital discharge or the day of a necessary second surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of spondylosis, pseudoarthrosis, kyphoscoliosis, or acquired or congenital spine deformity
  • Willing to undergo elective spinal surgery by a participating surgeon; eligible procedures include the following: spine osteotomy, arthrodesis, instrumentation and/or corpectomy, surgery for lumbar spinal stenosis, or surgery for degenerative disc disease

Exclusion criteria

  • Requires urgent or emergent surgery
  • Has kidney failure that requires dialysis
  • Has a known bleeding diathesis, defined as a documented history of an inherited bleeding disorder (e.g., hemophilia or von Willebrand's disease) OR prothrombin time ratio greater than 1.5 seconds OR a documented previous arterial or venous thrombosis within 1 year of study entry
  • Pregnant

Treatment and study plan

Epsilon-Aminocaproic Acid (EACA)

Drug

Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).

Placebo

Drug

Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).

Primary outcomes

  1. Number of allogenic blood units transfused

    Time frame: Measured through the 8th postoperative day

Secondary outcomes

  1. Intraoperative and postoperative blood loss

    Time frame: Measured through the 8th postoperative day

  2. Intraoperative and postoperative blood products received, including autologous blood, allogenic blood, fresh frozen plasma, platelets, or cryo

    Time frame: Measured through the 8th postoperative day

  3. Potential complications of transfusion

    Time frame: Measured through the 8th postoperative day

  4. Potential complications of EACA

    Time frame: Measured through the 8th postoperative day

  5. Potential surgical complications

    Time frame: Measured through the 8th postoperative day

  6. Duration of mechanical ventilation

    Time frame: Measured through the 8th postoperative day

  7. In-hospital mortality

    Time frame: Measured through the 8th postoperative day

  8. ICU length of stay (LOS)

    Time frame: Measured through the 8th postoperative day

  9. Hospital LOS

    Time frame: Measured through the 8th postoperative day

  10. Direct costs of hospital care

    Time frame: Measured through the 8th postoperative day

Sponsors and collaborators

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Nih

Registry information

Official study title

Aminocaproic Acid and Bleeding in Spinal Surgery

Important dates

Study start
2000
Primary completion
2006
Study completion
2006
First posted
May 3, 2006
Registry last updated
Jul 29, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.